MARTINEZ, Calif. – ExThera Medical, maker of the only effective pathogen-removal, hemoperfusion filter approved for patient use in Europe, and Fresenius Medical Care, the world’s leading provider of products and...
Read moreAn inventor of a Groundbreaking Device to Treat COVID-19 and other bloodstream infections, ExThera Medical’s CEO Robert Ward to be Recognized by BioMedSA for Innovation in Healthcare and Bioscience ExThera...
Read moreHeparin-based blood purification attenuates organ injury in baboons with S. pneumoniae pneumonia. Download the full article here
Read moreMARTINEZ, Calif. – ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100), a blood purification device with many potential applications including the treatment of sepsis, will be studied in...
Read moreHemofiltration with the Seraph®100 Microbind® Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients Download the full article here
Read moreMARTINEZ, Calif. – ExThera Medical’s Seraph 100® Microbind® Affinity Filter (Seraph 100) is now being distributed in Europe by Fresenius Medical Care, the world’s leading provider of products and services...
Read moreVall d’Hebron Barcelona Hospital Campus begins two clinical trials to test a new system to filter blood and improve the evolution of COVID-19 and sepsis Seraph 100 consists of a...
Read moreMARTINEZ, Calif. – ExThera Medical announced today the release of preliminary clinical study data demonstrating significantly improved survival rates among critically ill COVID-19 patients when treated with the Seraph® 100...
Read moreThe Seraph®100 Microbind Affinity Blood Filter® (Seraph 100) is an extracorporeal medical countermeasure that can remove many pathogens from blood, including the SARS-CoV-2 virus. The aim of this study was...
Read moreThis case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusionmight have positive effects on the clinical course of critically ill patients with COVID-19. Download the full...
Read more